Summary Background The international Intermediate Clinical Endpoints in Cancer of the
Prostate working group has established metastasis-free survival as a surrogate for overall …

Purpose Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer
decreases the number of deaths from this disease. Surrogates for overall survival (OS) could …

Background It is unclear whether adjuvant or early salvage radiotherapy following radical
prostatectomy is more appropriate for men who present with localised or locally advanced …

PURPOSE Recently, we have shown that metastasis-free survival is a strong surrogate for
overall survival (OS) in men with intermediate-and high-risk localized prostate cancer and …

Background Androgen suppression therapy and radiotherapy are used to treat locally
advanced prostate cancer. 3 years of androgen suppression confers a small survival benefit …

Context Different nonsurgical therapeutic strategies can be adopted for intraprostatic relapse
of prostate cancer after primary radiotherapy, including re-irradiation (with brachytherapy …

Background Treatment of the primary, termed local therapy (LT), may improve survival in
metastatic prostate cancer (mPCa) versus no local therapy (NLT). Objective To assess …

Background Choice of treatment in localised prostate cancer has been hampered by a lack
of unbiased, representative data on outcome. Most existing data have come from small …

BACKGROUND The role of local therapy, in the form of radiation therapy (RT) or radical
prostatectomy (RP), and its association on outcomes is not well established in patients with …

Purpose: We analyzed all available studies assessing the management of node only
recurrence after primary local treatment of prostate cancer. Materials and Methods: We …